(Q41941085)

14 October 2017

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival (English)

1 reference

14 October 2017

0 references

1 reference

M Ramos-Casals

2

0 references

author name string

A Sisó

1

1 reference

14 October 2017

A Bové

3

1 reference

14 October 2017

P Brito-Zerón

4

1 reference

14 October 2017

N Soria

5

1 reference

14 October 2017

S Muñoz

6

1 reference

14 October 2017

A Testi

7

1 reference

14 October 2017

J Plaza

8

1 reference

14 October 2017

J Sentís

9

1 reference

14 October 2017

A Coca

10

1 reference

14 October 2017

language of work or name

1 reference

1 April 2008

1 reference

14 October 2017

1 reference

14 October 2017

17

1 reference

14 October 2017

4

1 reference

14 October 2017

281-288

1 reference

Systemic lupus erythematosus

14 October 2017

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Biochemical characterization of ADP-ribose polymer metabolism in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Cardiovascular risk factors and the long-term outcome of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Sustained remission of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Antimalarials--the 'real' advance in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Antimalarials may influence the risk of malignancy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203307086503

21 January 2018

Identifiers

DOI

10.1177/0961203307086503

1 reference

14 October 2017

1 reference